This week, we review two studies from a Presidential Symposium at ESMO focusing on the efficacy of PARP inhibitors in patients with newly diagnosed ovarian cancer.

Coverage of stories discussed this week on ascopost.com:

ESMO 2019: Studies Show PARP Inhibitors Improve Survival, Reduce Risk of Disease Recurrence or Death in Newly Diagnosed Ovarian Cancer